Drug Pricing Transparency and Accountability Act
- Introduced Jan 9
- Committee Jan 9
- Passed House Next
- Passed Senate Not yet
- To President Not yet
- Law Not yet
Companies lobbying on this bill
2 companiesVotes
No recorded roll-call vote on this bill yet
Member trades
No member of Congress traded these companies in the last 90 days
Summary
Drug Pricing Transparency and Accountability Act
Full summary1 paragraphs
This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.
Library of Congress summary, Jan 9, 2023
- Introduced in HouseJan 9, 2023
Actions
- HouseReferred to the Subcommittee on Health.Dec 17, 2024
- HouseReferred to the Subcommittee on Health.Jan 20, 2023
- HouseIntroduced in HouseJan 9, 2023
- HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Jan 9, 2023
Bill record
Text versions1
- Introduced in HouseJan 9, 2023PDF: Introduced in House
Committees2
- House Ways and Means CommitteeReferred To Jan 9, 2023
- Subcommittee: Health SubcommitteeReferred to
- House Energy and Commerce CommitteeReferred To Jan 9, 2023
- Subcommittee: Health SubcommitteeReferred to
Sponsor and cosponsors0 cosponsors
- Rep. Matthew Rosendale (R-MT-2)Sponsor, Jan 9, 2023
Amendments0
No amendments offered
Cost estimates and reports0
No cost estimate or committee report yet
Titles2
- Drug Pricing Transparency and Accountability ActShort Title(s) as Introduced
- To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.Official Title as Introduced
Subjects16
Related bills1
- H.R. 5463 117th, Reintroduction of Drug Pricing Transparency and Accountability Act
Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.